Efficacy and safety of basal-meal insulin 2:2 and 2:3 regimens in hospitalized hyperglycemic patients: a randomized controlled clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050963

Enrollment

Unknown

Registered

2021-09-08

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

2:2 group:Starting dose: insulin glargine 0.2U/kg/d, insulin aspart 0.2U/kg/d divided into three meals. Adjusted dose: insulin glargine 0.1U/kg/d, insulin aspart 0.1U/kg/d divided into three meals

2:3 group:Starting dose: insulin glargine 0.2U/kg/d, insulin aspart 0.3U/kg/d divided into three meals. Adjusted dose: insulin glargine 0.1U/kg/d, insulin aspart 0.05U/kg/meal

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes; 2. Aged 18-75 years; 3. Admission random blood sugar>10.0mmol/L; 4. ALT and AST 45ml/min/1.73m^2; 6. Willing to take insulin; 7. Willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of tumor; 2. There is a history of using glucocorticoids in the past 1 year; 3. Pregnancy and lactation; 4. Severe mental illness.

Design outcomes

Primary

Measure	Time frame
fasting blood glucose;2 hour postprandial blood glucose ;	—

Countries

China

Contacts

Public ContactLi Wan'gen

The Second Affiliated Hospital of Guangzhou Medical University

liwg660@126.com+86 18926298645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026